Analyst Reports

  • 15 Oct 2024

    Edison Investment Research update
    Actinogen Medical – A$11.1m capital raise completed

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 07 Oct 2024

    Edison Investment Research update
    Actinogen Medical – Funding in place to complete XanaMIA Phase IIb

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 27 Aug 2024

    Edison Investment Research update
    Actinogen Medical – Further positive XanaCIDD results on depression

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 22 Aug 2024

    Edison Investment Research update
    Actinogen Medical – XanaCIDD data narrow the focus in depression

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 28 Jun 2024

    Edison Investment Research update
    Actinogen Medical – Publication of XanADu biomarker analysis

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 15 May 2024

    Edison Investment Research update
    Actinogen Medical – Funding in place through key catalysts

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 16 Apr 2024

    Edison Investment Research update
    Actinogen Medical – First patient dosed in Phase IIb XanaMIA study

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 29 Feb 2024

    Edison Investment Research update
    Pressing forward with Xanamem

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 22 Dec 2023

    Edison Investment Research update
    Phase IIb XanaMIA study opens first study site

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report
  • 25 Oct 2023

    Edison Investment Research update
    Taking steps to mitigate funding headwinds

    Analyst: Pooya Hemami

    This report has been commissioned and paid for by Actinogen Medical Limited (Company) and has been prepared by Edison Investment Research. The report solely reflects the views of Edison Investment Research.

    Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of Edison Investment Research at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

    Continue to report

Latest results

2024 Full Year Financial results

View Results Centre

2024 Annual General Meeting

Actinogen’s next Annual General Meeting

Date: 14 November 2024

Read more

Back
to top